Extracorporeal Immunopharmacotherapy Portal

About extracorporeal immunopharmacotherapy

Extracorporeal immunopharmacotherapy (EIFT) is a developing and increasingly popular innovative treatment method that combines elements of extracorporeal therapy and immunopharmacotherapy. Extracorporeal immunopharmacotherapy is a method of immunocorrection that uses immune system regulatory cells (lymphocytes, etc.) activated outside the body (extracorporeal) with pharmacological preparations.
Extracorporeal means “outside the body", which implies the use of devices, specialized equipment and technologies for processing blood (or other biological fluids), as well as procedures for preparing substances for treatment outside the patient's body.
• Immunotherapy is a treatment aimed at modulating the immune system to fight diseases. Treatment with immunological drugs that target the immune system in cases of impaired immune function – immunodeficiency, autoimmune diseases.
• Immunopharmacotherapy is the use of drugs to influence the immune system for the purpose of treatment.
The part of the word “pharmaco" (root – pharmacus, o – connective vowel) indicates the use of pharmacological agents, that is, drugs, in the treatment process.

Differences between EIFT and other methods:
Extracorporeal immunotherapy uses methods aimed at modulating the immune system outside the body, but without using pharmacological agents.
• Plasmolifting uses the patient's platelet-rich blood plasma to stimulate tissue regeneration.
• PRP therapy is a method similar to plasmolifting, but using platelet-rich plasma to a greater extent.
• ORTOKINE therapy uses the patient's cytokine-rich IL-1Ra blood serum to treat inflammatory processes.
Unlike extracorporeal immunotherapy, which can only involve the modulation of the immune system without the use of drugs, EIFT combines both approaches, which allows for a more accurate and effective effect on the immune system.
EIFT differs from such methods as plasmolifting, PRP therapy, and ORTOKINE therapy in that it aims to have a deeper and more comprehensive effect on the immune system using pharmacological agents.

Advantages of EIFT:
• Highly effective in the treatment of chronic and immune diseases.
• The ability to fine-tune treatment to the specific needs of the patient, which makes it particularly effective in the treatment of chronic and complex immune diseases.
• Minimization of side effects due to the local use of drugs.

Extracorporeal immunopharmacotherapy is at the stage of active development and implementation in clinical practice. New research and clinical trials are continuing, which opens up new perspectives for this method.

Portal tasks

The extracorporeal Immunopharmacotherapy portal was created to bring together specialists in this field in order to:
• Creation of a community of specialists in the field of extracorporeal immunopharmacotherapy.
• Exchange of experience.
• Solutions to complex medical issues.
• Expanding the sphere of influence of extracorporeal immunopharmacotherapy.
• Introduction of new techniques and technologies.

Benefits for specialists:
• Joining a community of like-minded people to share knowledge and experience.
• Participation in the forum to discuss current issues and problems.
• Access to the latest research and clinical data.
• Opportunity for training and advanced training.
• Expanding the network of contacts.

Benefits for specialists in other fields:
• Expanding knowledge in related fields of medicine.
• The ability to integrate new methods into your practice.
• Participation in projects and research.

Creating a community of like-minded people allows you to share experiences, discuss complex cases and find optimal solutions for the treatment of patients.
Specialists can acquire new knowledge in the field of extracorporeal immunopharmacotherapy, as well as in related areas of medicine, learn about the latest achievements and innovations, as well as gain access to exclusive materials and research.
Specialists can acquire new knowledge and skills by participating in webinars, seminars and other educational events organized by the company.

Extracorporeal immunopharmacotherapy technologies

Mastering new technologies:
• The opportunity to study and implement advanced treatment methods.
• Development and testing of own technologies and techniques.
• Participation in major projects and research.


Privileged conditions:
• Access to the latest technologies on exclusive terms.
• The opportunity to become a leader in the use of modern treatment methods.


The prospects:

• Development of new technologies and treatment methods.
• Implementation of modern technologies in clinical practice.

The portal provides unique opportunities for the development of new treatment technologies, the introduction of their own developments and participation in major projects. Specialists can use new technologies on privileged terms, which allows them to become leaders in their field.
To get acquainted with new technologies, participate in projects and implement your developments, you need to contact us.

The prospects for the development of new technologies of extracorporeal immunopharmacotherapy include:
• Development and implementation of innovative treatment methods.
• Improving the efficiency and safety of procedures.
• Expanding the use of extracorporeal immunopharmacotherapy in world practice.


Modern technologies in this field continue to evolve, opening up new opportunities for the treatment of various diseases and improving the quality of life of patients.

Specialists can implement their own developments and technologies, participate in large projects and use the latest achievements on privileged terms.